Most types of hereditary angioedema (HAE) are worsened by endogenous or exogenous estrogens. Conversely, androgens can improve HAE with abnormal C1-Inhibitor (C1-INH) by increasing C1-INH concentrations. Menopause is associated with an extinction of ovarian estrogenic and androgenic secretion. There is currently insufficient information on postmenopausal women with HAE. The objective of this study was to describe the activity of HAE in postmenopausal women.
This was a French retrospective, multicenter study in postmenopausal women with HAE with or without C1-INH deficiency/dysfunction. The patients were classified before and after menopause with a previously validated HAE disease severity score.
We included 65 women from 13 centers in France. The mean age was 62.7± 9.2 years, and the mean time between menopause and inclusion was 12.5± 9.1 years. HAE was associated with C1-INH deficiencyin 88% (n = 57) of the patients, a mutation of factor 12 in 8% (n = 5), a mutation in plasminogen gene in one, and unknown HAE for two. The HAE course was not different after menopause in 46.1% (n = 30), improved in 38.5% (n = 25), and worsened in 15.4% (n = 10). Improvement was correlated with estrogen sensitivity of angioedema before menopause (p = 0.06 for improvement vs no effect or worsening). In addition, we observed that only ten women received treatment (transdermal or oral estradiol+ progestogen) for their menopause symptoms. Among them, only 3 experienced worsening of symptoms (2 on transdermal and 1 on oral estradiol).
Following menopause, most women with HAE remain stable but some worsen. Improvement was mainly observed in patients with previous estrogen sensitivity. More research is required in menopausal women with HAE to better understand how to manage climacteric symptoms.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Hereditary angioedema with C1-Inhibitor deficiency/dysfunction
Hereditary angioedema with normal C1-Inhibitor
Plasma-derived concentrate C1-Inhibitor
Estroprogestin combined (oral) contraception
Menopause hormone treatment
Body mass index
Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69:602–16.
Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hébert J, Kanani A, et al. The International/Canadian Hereditary Angioedema Guideline. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol [Internet]. 2019 [cited 2020 Mar 30];15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878678/.
Wu MA, Perego F, Zanichelli A, Cicardi M. Angioedema phenotypes: disease expression and classification. Clin Rev Allergy Immunol. 2016;51:162–9.
Zuraw BL, Bork K, Binkley KE, Banerji A, Christiansen SC, Castaldo A, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012;33(Suppl 1):S145–56.
Bova MC, Bafunno V, et al. Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor allergy. Allergy. 2020 Jun;75(6):1394-1403. https://doi.org/10.1111/all.14160
Lopes Veronez C, Sevciovic Grumach A. Angioedema without urticaria: novel findings which must be measured in clinical setting. Curr Opin Allergy Clin Immunol. 2020 Jun;20(3):253–60.
Banday AZ, Jindal AK, EAwat A, Singh S. An update on the genetics and pathogenesis of hereditary angioedema. Genes Dis. 2019;7(1):75–83.
Bork K, Wulff K, Steinmüller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy. 2017;00:1e9.
Bafunno V, Firinu D, D’Apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol. 2018;141:1009e1117.
Bork K, Wulff K, Rossmann H, Steinmüller-Magin L, Braenne I, Witzke G, et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin. Allergy. 2019;74:2479–81.
Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129:308–20.
Bouillet L, Longhurst H, Boccon-Gibod I, Bork K, Bucher C, Bygum A, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199:484.e1–4.
Gompel A, Fain O, Boccon-Gibod I, Gobert D, Bouillet L. Exogenous hormones and hereditary angioedema. Int Immunopharmacol. 2020;78:106080.
Zotter Z, Csuka D, Szabó E, Czaller I, Nébenführer Z, Temesszentandrási G, et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2014;9:44.
Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976;295:1444–8.
Heinemann LAJ, DoMinh T, Strelow F, Gerbsch S, Schnitker J, Schneider HPG. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes. 2004;2:67.
MRS - Menopause Rating Scale [Internet]. [cited 2020 Apr 25]. Available from: http://www.menopause-rating-scale.info/.
Prior N, Remor E, Pérez-Fernández E, Caminoa M, Gómez-Traseira C, Gayá F, et al. Psychometric field study of hereditary angioedema quality of life questionnaire for adults: HAE-QoL. J Allergy Clin Immunol Pract. 2016;4:464–473.e4.
Bouillet L, Launay D, Fain O, Boccon-Gibod I, Laurent J, Martin L, et al. Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patient. Ann Allergy Asthma Immunol. 2013;111(4):290–4.
Visy B, Füst G, Varga L, Szendei G, Takács E, Karádi I, et al. Sex hormones in hereditary angioneurotic oedema. Clin Endocrinol. 2004;60:508–15.
Poortman J, Thijssen JH, de Waard F. Plasma oestrone, oestradiol and androstenedione levels in post-menopausal women: relation to body weight and height. Maturitas. 1981;3:65–71.
Luyer MD, Khosla S, Owen WG, Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab. 2001;86:3629–34.
Madsen JS, Kristensen SR, Gram J, Bladbjerg EM, Henriksen FL, Gram J, et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women. J Thromb Haemost JTH. 2003;1:1984–91.
Thiery M, Vermeulen A, Baele G, Deslypere JP. Effects of a very low-estrogen oral contraceptive on clotting factors, carbohydrate metabolism and plasma lipids and lipoproteins. Med Sci Res. 1987;15:1231–2.
Gallagher PE, Li P, Lenhart JR, Chappell MC, Brosnihan KB. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertens Dallas Tex 1979. 1999;33:323–8.
Nogawa N, Sumino H, Ichikawa S, Kumakura H, Takayama Y, Nakamura T, et al. Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women. Menopause N Y N. 2001;8:210–5.
Sumino H, Ichikawa S, Ohyama Y, Nakamura T, Kanda T, Sakamoto H, et al. Effects of hormone replacement therapy on serum angiotensin-converting enzyme activity and plasma bradykinin in postmenopausal women according to angiotensin-converting enzyme-genotype. Hypertens Res Off J Jpn Soc Hypertens. 2003;26:53–8.
McGlinchey PG, McCluskey DR. Hereditary angioedema precipitated by estrogen replacement therapy in a menopausal woman. Am J Med Sci. 2000;320:212–3.
Rousset-Jablonski C, Thalabard J-C, Gompel A. Tamoxifen contraindicated in women with hereditary angioedema? Ann Oncol Off J Eur Soc Med Oncol. 2009;20:1281–2.
Ichikawa J, Sumino H, Ichikawa S, Ozaki M. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens. 2006;19:744–9.
Ichikawa A, Sumino H, Ogawa T, Ichikawa S, Nitta K. Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin- aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women. Geriatr Gerontol Int. 2008;8:259–64.
Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women. Menopause N Y N. 2012;19:886–93.
Ott HW, Mattle V, Hadziomerovic D, Licht P, Döinghaus K, Rubbert A, et al. Treatment of hereditary angioneurotic oedema (HANE) with tibolone. Clin Endocrinol. 2007;66:180–4.
Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001;76:231–8.
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:3975–4011.
Del Pup L, Postruznik D, Corona G. Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: a pilot study. Maturitas. 2012;72:93–4.
Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35:75–83.
Hager K, Setzer J, Vogl T, Voit J, Platt D. Blood coagulation factors in the elderly. Arch Gerontol Geriatr. 1989;9:277–82.
Pérez V, Velarde V, Acuña-Castillo C, Gómez C, Nishimura S, Sabaj V, et al. Increased kinin levels and decreased responsiveness to kinins during aging. J Gerontol A Biol Sci Med Sci. 2005;60:984–90.
Sierra F. Both T- and K-kininogens increase in the serum of old rats but by different mechanisms. Mech Ageing Dev. 1995;84:127–37.
Feng W, Xu X, Zhao G, Zhao J, Dong R, Ma B, et al. Increased age-related cardiac dysfunction in Bradykinin B2 receptor-deficient mice. J Gerontol A Biol Sci Med Sci. 2016;71:178–87.
Kintsurashvili E, Duka A, Ignjacev I, Pattakos G, Gavras I, Gavras H. Age-related changes of bradykinin B1 and B2 receptors in rat heart. Am J Physiol Heart Circ Physiol. 2005;289:H202–5.
Nurmi L, Heikkilä HM, Vapaatalo H, Kovanen PT, Lindstedt KA. Downregulation of Bradykinin type 2 receptor expression in cardiac endothelial cells during senescence. J Vasc Res. 2012;49:13–23.
Montgomery RR, Shaw AC. Paradoxical changes in innate immunity in aging: recent progress and new directions. J Leukoc Biol. 2015;98(6):937–43.
Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404–11.
Moreau KL, Stauffer BL, Kohrt WM, Seals DR. Essential role of estrogen for improvements in vascular endothelial function with endurance exercise in postmenopausal women. J Clin Endocrinol Metab. 2013;98:4507–15.
Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006;444:847–53.
Kleniewski J, Czokało M. Plasma kininogen concentration: the low level in cord blood plasma and age dependence in adults. Eur J Haematol. 1991;46:257–62.
Centre de Référence sur les angiœdèmes à kinines [CRéAk] includes S. Amarger, MD (CHU Estaing, Clermont Ferrand, France), C. Blanchard-Delaunay, MD (CH Niort, France), B. Coppere, MD (Hospices Civils de Lyon, CHU Edouard Herriot, Lyon, France), A. DuThanh, MD (CHU Montpellier, France), B. Floccard, MD (Hospices Civils de Lyon, CHU Edouard Herriot, Lyon, France), S. Gayet, MD (Hospital La Timone, APHM, Marseille, France), P. Y. Jeandel, MD (CHU Nice, France), L. Martin, MD PhD (CHU Angers, France), F. Pelletier, MD (CRHU Besançon, France), F. N. Raison Peyron, MD (Hospital St Eloi, Montpellier, France). Thanks to Felicity Neilson for editing the manuscript in English.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of Interest
AB: no conflict of interest, OF: Consultant arrangements for Shire/Takeda and Behring, travel and accommodation to a Congress from GSK, honorarium for a talk from Sanofi, DL: consultant arrangements, research grant and travel and accommodation from Actelion, GSK, Octapharma, Pfizer, and Shire/Takeda. LB: Consultant arrangements, research grant and travel and accommodation from Shire/Takeda, CSL Behring, Pharming, GSK, Novartis, Sanofi. I B-G: Consultant arrangements, research grant, travel and accommodation from Shire/Takeda, CSL Behring, Pharming, Biocryst, Novartis DG: Consultant arrangements for Shire/Takeda honorarium for talks for Shire/Takeda, travel and accommodation from Shire/Takeda et Pharming. G.P-B: no conflict of interest. AG: member of an advisory board for Mithra (Estetrol).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Billebeau, A., Fain, O., Launay, D. et al. Hereditary Angioedema with and Without C1-Inhibitor Deficiency in Postmenopausal Women. J Clin Immunol 41, 163–170 (2021). https://doi.org/10.1007/s10875-020-00902-7
- Hereditary angioedema